Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure

Cytokine

Volumn 43, Issue 1, 2008, Pages 98-101

  Pawlak, Krystyna ^a   Mysliwiec, Michal ^a   Pawlak, Dariusz ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

Chronic renal failure; Oxidative stress; Phosphates; VEGF

Indexed keywords

C REACTIVE PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; CREATININE; INTERLEUKIN 6; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; UREA; VASCULOTROPIN;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; UREA BLOOD LEVEL; URINARY EXCRETION;

ADULT; BIOLOGICAL MARKERS; CREATININE; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHOSPHATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 45449088664     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2008.03.011     Document Type: Article

References (25)

1. Menon V., Gul A., and Sarnak M.J. Cardiovascular risk factors in chronic kidney disease. Kidney Int 68 (2005) 1413-1418
2. Foley R.N., Parfrey P., and Samak M.J. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 32 (1998) Suppl 3
3. Stenvinkel P., Heimburger O., Paultre F., Diczfalusy U., Wang T., Berglund L., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55 (1999) 1899-1911
4. Panichi V., Migliori M., De Pietro S., Taccola D., Bianchi A.M., Norpoth M., et al. C reactive protein in patients with chronic renal diseases. Ren Fail 23 (2001) 551-562
5. Diepeveen S.H.A., Verhoeven G.H.W.E., van der Palen J., Dikkeshei B.L.D., van Tits L.J., Kolsters G., et al. Oxidative stress in patients with end-stage renal disease prior to the renal replacement therapy. Nephron Clin Pract 98 (2004) c3-c7
6. Pecoits-Filho R., Heimburger O., Barany P., Suliman M., Fehrman-Ekholm I., Lindholm B., et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 41 (2003) 1212-1218
7. Dounousi E., Papavasiliou M., Makedou A., Ioannou K., Katopodis K.P., Tselepis A., et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 48 (2006) 752-760
8. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
9. Lemström K.B., Krebs R., Nykänen A.J., Tikkanen J.M., Sihvola R.K., Aaltola E.M., et al. Vascular endothelial growth factor enhances cardiac allograft atherosclerosis. Circulation 105 (2000) 2524-2530
10. Hovind P., Tarnow L., Oestergaard P.B., and Parving H.-H. Elevated plasma endothelial growth factor in type I diabetic patients with diabetic nephropathy. Kidney Int 59 (2001) 702-709
11. 121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int 60 (2001) 1297-1308
12. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., and Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 7 (2001) 425-429
13. Doi K., Noiri E., Nakao A., Fujita T., Kobayashi S., and Tokunaga K. Functional polymorphism in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males. J Am Soc Nephrol 17 (2006) 823-830
14. Harper S.J., Downs L., Tomson C.R.V., Dwight J.S.J., and Bolton C. Elevated plasma vascular endothelial growth factor lvels in non-diabetic predialysis uraemia. Nephron 90 (2002) 341-343
15. Pawlak K., Pawlak D., and Mysliwiec M. Possible association between circulating vascular endothelial growth factor and oxidative stress markers in hemodialysis patients. Med Sci Monit 12 (2006) CR181-CR185
16. National Kidney Foundation K/DOQI: clinical practice guide-lines for chronic kidney disease: evaluation, classification, and stratification. Am J Kideney Dis 2002;39:S1-266.
17. Pawlak K., Pawlak D., and Mysliwiec M. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clin Biochem 38 (2005) 700-705
18. Feliers D., Gorin Y., Ghosh-Choudhury G., About H.E., and Kasinath B.S. Angiotensin II stimulation of VEGF mRNA translation requires production of reactive oxygen species. Am J Physiol Renal Physiol 290 (2006) F927-F936
19. Roller R.E., Renner W., Dorr A., Pilger E., and Schnedl W.J. Oxidative stress and increase of vascular endothelial growth factor in plasma of patients with peripheral arterial occlusive disease. Thromb Haemost 85 (2001) 368
20. Block G.A., Hulbert-Shearon T.E., Levin N.W., and Port F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31 (1998) 607-617
21. Moe S.M., Duan D., Doehle B.P., O'Neill K.D., and Chen N.X. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63 (2003) 1003-1011
22. Chertow G.M., Burke S.K., and Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62 (2002) 245-252
23. Schwarz U., Buzello M., Ritz E., Stein G., Raabe G., Wiest G., et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal disease. Nephrol Dial Transplant 15 (2000) 218-223
24. Ishimura E., Taniwaki H., Tabata T., Tsujimoto Y., Jono S., Emoto M., et al. Cross-sectional association of serum phosphate with carotid intima-media thickness in hemodialysis patients. Am J Kidney Dis 45 (2005) 859-865
25. Phan O., Ivanovski O., Nguyen-Khoa T., Mothu N., Angulo J., Westenfeld R., et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 112 (2005) 2875-2882